Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy

NCT05792878
unknown

Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention

NCT04030039
unknownphase_4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

NCT02838810

Clinical Trials (3)

Showing 3 of 3 trials
NCT05792878

Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy

Unknown
NCT04030039

Cohort Study of Clinical Outcomes in Chronic HBV Infection Patients With Low HBsAg Under Unplanned Intervention

Unknown
NCT02838810Phase 4

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3